Skip to main content
锦好医疗 logo

锦好医疗 — Investor Relations & Filings

Ticker · 920925 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 568 across all filing types
Latest filing 2024-04-14 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920925

About 锦好医疗

https://www.jinghao.cn/

Jinghao Medical specializes in the research, development, and manufacturing of hearing aids and home medical electronic products. The company's core portfolio includes digital and analog hearing aids, medical nebulizers, and electronic blood pressure monitors. It focuses on providing hearing health solutions by integrating advanced digital signal processing technology into its devices. Jinghao Medical operates extensively in the global market, offering original design manufacturing (ODM) and original equipment manufacturing (OEM) services to international partners. The organization emphasizes technological innovation and maintains rigorous quality management systems to comply with international medical device standards. Its primary objective is to deliver accessible, high-performance medical equipment designed to improve the quality of life for users with hearing loss and other chronic health conditions.

Recent filings

Filing Released Lang Actions
2023年年度报告业绩说明会预告暨落实“提质守信重回报”行动公告
Investor Presentation Classification · 95% confidence The document is a notice from Huizhou Jinghao Medical Technology Co., Ltd. announcing a 2023 Annual Report Earnings Explanation Meeting (业绩说明会). It references the 2023 Annual Report and its summary already disclosed on March 25, 2024, and invites investors to participate in an online meeting on April 19, 2024, to discuss the annual report results. The document is short (1346 characters) and serves as an announcement of the upcoming earnings explanation meeting rather than the report itself. It does not contain actual financial statements or detailed financial analysis. Therefore, it is best classified as an Investor Presentation (IP) type document, as it focuses on a presentation event for investors to explain the annual report results and engage with investors.
2024-04-14 Chinese
关于公司被认定为2023年度广东省工程技术研究中心的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Huizhou Jin Hao Medical Technology Co., Ltd. regarding its recognition as the 2023 Guangdong Provincial Engineering Technology Research Center. It includes a description of the recognition, its impact on the company, and a risk warning. There are no financial statements, no mention of annual or quarterly results, no audit information, no management changes, no voting results, no legal proceedings, no capital changes, and no investor presentations. The document is short (812 characters) and serves as a regulatory announcement about a company recognition event. It does not fit into financial report categories but is a regulatory announcement about a company event. Therefore, the best fitting category is Regulatory Filings (RNS).
2024-04-14 Chinese
2023年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as a "2023年度权益分派预案公告" which translates to "2023 Annual Equity Distribution Plan Announcement." It details the company's plan for cash dividend distribution based on audited 2023 financial results, including the dividend amount per share, total dividend payout, and references to the company's retained earnings and profit distribution policies. It also includes information about board and supervisory committee approvals and mentions that the plan is subject to shareholder meeting approval. The document is an announcement of a dividend distribution plan rather than the actual dividend payment notice or a full annual report. It is not a full financial report but a specific announcement about the dividend proposal. Therefore, the most appropriate classification is "Notice of Dividend Amount (DIV)." The document length is 2615 characters, which is consistent with an announcement rather than a full report.
2024-03-24 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is a comprehensive report from Huizhou JingHao Medical Technology Co., Ltd. covering the fiscal year 2023. It includes detailed sections such as company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management details, industry information, corporate governance, internal controls, and full financial accounting reports. The presence of audited financial statements, management's discussion and analysis, risk factors, and detailed financial metrics indicates this is a full annual report. The document also references an audit report with an unqualified opinion, which is typical for an annual report. The length (15,000 characters) and depth of content confirm it is not a mere announcement or summary but the full official yearly report. Therefore, the appropriate classification is Annual Report (10-K). FY 2023
2024-03-24 Chinese
第三届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Huizhou Jin Hao Medical Technology Co., Ltd. It details the meeting date, attendance, and the approval of several proposals related to the 2023 annual report, financial statements, equity distribution plan, and other reports. The document references that the actual 2023 annual report and other detailed reports are published separately on the Beijing Stock Exchange disclosure platform, indicating this document is not the full annual report itself but a meeting resolution announcing decisions and approvals. The document length is 2256 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS) as it is a formal announcement of meeting resolutions and approvals rather than the full annual report or financial statements themselves.
2024-03-24 Chinese
监事会关于2022年股票期权激励计划第一个行权期行权条件成就的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement by the supervisory board of Huizhou Jin Hao Medical Technology Co., Ltd. regarding the verification and confirmation of conditions related to the company's 2022 stock incentive plan, specifically the first exercise period of stock options. It references compliance with relevant laws, regulations, and the company's articles of association. The document is an official announcement about the status and approval of stock option exercises rather than a full report or detailed financial statement. It does not contain financial data or detailed analysis but rather a regulatory compliance and status update on stock incentives. This fits best under Regulatory Filings (RNS) as it is a compliance announcement and verification statement related to stock incentive plans, not a full capital/financing update or a detailed report.
2024-03-24 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.